Latigo Biotherapeutics posts Q2 FY26 net loss of $25.8 million; G&A expenses rise 64.29% to $4.6 million

PUBT · 2d ago
Latigo Biotherapeutics posts Q2 FY26 net loss of $25.8 million; G&A expenses rise 64.29% to $4.6 million
  • Latigo posted a net loss of USD 25.8 million for Q2 2026, unchanged from Q2 2025.
  • R&D expense slipped 7.42% to USD 21.2 million, while G&A expense climbed 64.29% to USD 4.6 million.
  • Cash and cash equivalents totaled USD 55 million at June 30, 2026; net IPO proceeds are expected to fund operations into 2029.
  • Completed an upsized IPO in August, raising USD 397.4 million in gross proceeds, including the full underwriters’ option exercise.
  • Plans Phase 3 onzotrigine trials in H2 2026; expects topline bunionectomy and safety data in H2 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Latigo Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-381912), on September 03, 2026, and is solely responsible for the information contained therein.